Emergent BioSolutions provides specialty products for civilian and military populations that address intentional and naturally emerging public health threats.

At Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve …

May 15, 2023 · Emergent is built on the foundation of an inclusive, values-driven culture; one with high employee engagement and where a diversity of experiences, backgrounds, and skills …

As such, Emergent has discontinued production of Trobigard, and the product is no longer available; however, we remain committed to public health preparedness and will continue to …

Emergent BioSolutions Reports Financial Results For Third Quarter 2021. Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, …

Emergent has spent the last 25 years at the forefront of public health. We work to increase access to life-saving products like NARCAN® Nasal Spray 4 mg and KLOXXADO ® (naloxone HCI) …

Emergent has expertise with FDA-approved human and equine plasma products generated for targeted therapy of specific indications. Our hyperimmune specialty plasma product …

Emergent BioSolutions CEO: ‘Confrontational’ coverage of vaccine maker puts a target on ‘people doing good’ | COMMENTARY. As the CEO of a 2,000-plus person Maryland-based company …

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa …

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development …